Olfactory Training in Post-COVID-19 Persistent Olfactory Disorders: Value Normalization for Threshold but Not Identification.

Clair Vandersteen, Magali Payne, Louise-Émilie Dumas, Élisa Cancian, Alexandra Plonka, Grégoire D'Andréa, David Chirio, Élisa Demonchy, Karine Risso, Florence Askenazy-Gittard, Charles Savoldelli, Nicolas Guevara, Philippe Robert, Laurent Castillo, Valeria Manera, Auriane Gros
Author Information
  1. Clair Vandersteen: Institut Universitaire de la Face et du Cou, Centre Hospitalier Universitaire, Université Côte d'Azur, 31 Avenue de Valombrose, 06100 Nice, France. ORCID
  2. Magali Payne: Laboratoire CoBTeK, Université Côte d'Azur, 06100 Nice, France.
  3. Louise-Émilie Dumas: Laboratoire CoBTeK, Université Côte d'Azur, 06100 Nice, France.
  4. Élisa Cancian: Institut Universitaire de la Face et du Cou, Centre Hospitalier Universitaire, Université Côte d'Azur, 31 Avenue de Valombrose, 06100 Nice, France.
  5. Alexandra Plonka: Laboratoire CoBTeK, Université Côte d'Azur, 06100 Nice, France. ORCID
  6. Grégoire D'Andréa: Institut Universitaire de la Face et du Cou, Centre Hospitalier Universitaire, Université Côte d'Azur, 31 Avenue de Valombrose, 06100 Nice, France. ORCID
  7. David Chirio: Département de Médecine Infectiologique, Hôpital de l'archet, Centre Hospitalier Universitaire, Université Côte d'Azur, 151 Route de Saint-Antoine, 06200 Nice, France.
  8. Élisa Demonchy: Département de Médecine Infectiologique, Hôpital de l'archet, Centre Hospitalier Universitaire, Université Côte d'Azur, 151 Route de Saint-Antoine, 06200 Nice, France.
  9. Karine Risso: Département de Médecine Infectiologique, Hôpital de l'archet, Centre Hospitalier Universitaire, Université Côte d'Azur, 151 Route de Saint-Antoine, 06200 Nice, France.
  10. Florence Askenazy-Gittard: Laboratoire CoBTeK, Université Côte d'Azur, 06100 Nice, France.
  11. Charles Savoldelli: Institut Universitaire de la Face et du Cou, Centre Hospitalier Universitaire, Université Côte d'Azur, 31 Avenue de Valombrose, 06100 Nice, France.
  12. Nicolas Guevara: Institut Universitaire de la Face et du Cou, Centre Hospitalier Universitaire, Université Côte d'Azur, 31 Avenue de Valombrose, 06100 Nice, France. ORCID
  13. Philippe Robert: Laboratoire CoBTeK, Université Côte d'Azur, 06100 Nice, France. ORCID
  14. Laurent Castillo: Institut Universitaire de la Face et du Cou, Centre Hospitalier Universitaire, Université Côte d'Azur, 31 Avenue de Valombrose, 06100 Nice, France.
  15. Valeria Manera: Laboratoire CoBTeK, Université Côte d'Azur, 06100 Nice, France.
  16. Auriane Gros: Laboratoire CoBTeK, Université Côte d'Azur, 06100 Nice, France.

Abstract

(1) Background: Persistent post-viral olfactory disorders (PPVOD) are estimated at 30% of patients one year after COVID-19 infection. No treatment is, to date, significantly effective on PPVOD with the exception of olfactory training (OT). The main objective of this work was to evaluate OT efficiency on post-COVID-19 PPVOD. (2) Methods: Consecutive patients consulting to the ENT department with post-COVID-19 PPVOD were included after completing clinical examination, the complete Sniffin’ Stick Test (TDI), the short version of the Questionnaire of olfactory disorders and the SF-36. Patients were trained to practice a self-olfactory training with a dedicated olfactory training kit twice a day for 6 months before returning to undergo the same assessments. (3) Results: Forty-three patients were included and performed 3.5 months of OT in average. We observed a significant TDI score improvement, increasing from 24.7 (±8.9) before the OT to 30.9 (±9.8) (p < 0.001). Based on normative data, a significant increase in the number of normosmic participants was observed only for the threshold values (p < 0.001). Specific and general olfaction-related quality of life improved after the OT. (4) Conclusions: Olfactory function appeared to improve only in peripheral aspects of post-COVID-19 PPVOD after OT. Future controlled studies must be performed to confirm the OT role and justify new therapeutic strategies that may focus on the central aspects of post-COVID-19 PPVOD.

Keywords

References

  1. Eur Arch Otorhinolaryngol. 2022 Jul;279(7):3477-3484 [PMID: 34716806]
  2. Laryngoscope. 2009 Mar;119(3):496-9 [PMID: 19235739]
  3. Front Physiol. 2021 Jan 26;11:625110 [PMID: 33574768]
  4. Rhinology. 2021 Dec 1;59(6):517-527 [PMID: 34553706]
  5. J Laryngol Otol. 2020 Aug;134(8):703-709 [PMID: 32782030]
  6. Laryngoscope. 2012 Jul;122(7):1450-4 [PMID: 22566102]
  7. Chem Senses. 2014 Mar;39(3):185-94 [PMID: 24429163]
  8. Am J Otolaryngol. 2021 Mar-Apr;42(2):102884 [PMID: 33429174]
  9. JAMA Otolaryngol Head Neck Surg. 2014 Oct;140(10):951-5 [PMID: 25170573]
  10. Neuroimage Clin. 2015 Sep 15;9:401-10 [PMID: 26594622]
  11. Curr Opin Psychiatry. 2021 Mar 1;34(2):177-185 [PMID: 33395100]
  12. ORL J Otorhinolaryngol Relat Spec. 2019;81(4):185-192 [PMID: 31238309]
  13. EClinicalMedicine. 2020 Aug;25:100484 [PMID: 32838240]
  14. J Otolaryngol Head Neck Surg. 2020 May 4;49(1):26 [PMID: 32366299]
  15. Biomedicines. 2021 Mar 12;9(3): [PMID: 33808956]
  16. J Neurophysiol. 2007 Oct;98(4):2196-205 [PMID: 17699692]
  17. Brain Imaging Behav. 2017 Aug;11(4):998-1005 [PMID: 27448159]
  18. Eur Arch Otorhinolaryngol. 2021 Dec;278(12):4831-4837 [PMID: 33774737]
  19. Rhinology. 2021 Feb 1;59(1):26-31 [PMID: 33320115]
  20. J Clin Exp Neuropsychol. 2010 Dec;32(10):1062-7 [PMID: 20437286]
  21. Otolaryngol Head Neck Surg. 2021 Feb;164(2):244-254 [PMID: 32660334]
  22. Eur Arch Otorhinolaryngol. 2022 Jan;279(1):515-520 [PMID: 33963433]
  23. Eur Arch Otorhinolaryngol. 2019 Mar;276(3):719-728 [PMID: 30554358]
  24. J Clin Epidemiol. 1995 Aug;48(8):1051-60 [PMID: 7775992]
  25. Cochrane Database Syst Rev. 2021 Jul 22;7:CD013877 [PMID: 34291812]
  26. Laryngoscope. 2018 Jul;128(7):1518-1522 [PMID: 29114936]
  27. Rehabil Psychol. 2009 Nov;54(4):404-412 [PMID: 19929122]
  28. J Intern Med. 2021 Aug;290(2):451-461 [PMID: 33403772]
  29. Rhinology. 2017 Mar 1;55(1):17-26 [PMID: 28040824]
  30. Int Forum Allergy Rhinol. 2019 Oct;9(10):1144-1150 [PMID: 31430061]
  31. J Laryngol Otol. 2021 May;135(5):436-441 [PMID: 33888166]
  32. Laryngoscope. 2014 Apr;124(4):826-31 [PMID: 23929687]
  33. Neuroscience. 2011 Mar 17;177:177-82 [PMID: 21241781]
  34. Chem Senses. 1997 Feb;22(1):39-52 [PMID: 9056084]
  35. Neural Plast. 2014;2014:140419 [PMID: 25544900]
  36. Int Forum Allergy Rhinol. 2021 Nov;11(11):1592-1595 [PMID: 34148294]
  37. Acad Radiol. 2020 Jul;27(7):1042-1043 [PMID: 32386948]
  38. Eur Arch Otorhinolaryngol. 2021 Aug;278(8):3113-3117 [PMID: 33423106]
  39. Chem Senses. 2020 Dec 5;45(9):875-881 [PMID: 33033827]
  40. Laryngoscope. 2021 May;131(5):1095-1100 [PMID: 33404079]
  41. PLoS One. 2021 Nov 9;16(11):e0259321 [PMID: 34752471]
  42. Clin Exp Pharmacol Physiol. 2022 Apr;49(4):462-473 [PMID: 35090056]
  43. Laryngoscope Investig Otolaryngol. 2018 Feb 21;3(2):94-99 [PMID: 29721540]
  44. Otolaryngol Head Neck Surg. 2022 Jul;167(1):183-186 [PMID: 34813382]
  45. Alzheimers Dement. 2021 Jun;17(6):1056-1065 [PMID: 33399270]
  46. Int Forum Allergy Rhinol. 2021 Aug;11(8):1249-1252 [PMID: 33539667]
  47. Alzheimers Res Ther. 2020 Jun 4;12(1):69 [PMID: 32498691]
  48. Int Arch Otorhinolaryngol. 2020 Apr;24(2):e237-e246 [PMID: 32296471]
  49. Int Forum Allergy Rhinol. 2022 Feb 23;: [PMID: 35199476]
  50. Rhinology. 2018 Dec 1;56(4):330-335 [PMID: 30076701]
  51. Laryngoscope. 2008 Jan;118(1):135-44 [PMID: 17975508]
  52. J Affect Disord Rep. 2021 Jul;5:100156 [PMID: 34075369]
  53. Rhinol Suppl. 2017 Mar;54(26):1-30 [PMID: 29528615]
  54. Sci Transl Med. 2021 Jun 2;13(596): [PMID: 33941622]
  55. Pathogens. 2021 Jun 04;10(6): [PMID: 34199734]
  56. Ear Nose Throat J. 2021 Aug 31;:1455613211032004 [PMID: 34463149]

Word Cloud

Created with Highcharts 10.0.0OTPPVODolfactorytrainingpost-COVID-19disorderspatientsOlfactoryPersistentCOVID-19includedTDImonths3performedobservedsignificant9p<0001aspects1Background:post-viralestimated30%oneyearinfectiontreatmentdatesignificantlyeffectiveexceptionmainobjectiveworkevaluateefficiency2Methods:ConsecutiveconsultingENTdepartmentcompletingclinicalexaminationcompleteSniffin’StickTestshortversionQuestionnaireSF-36Patientstrainedpracticeself-olfactorydedicatedkittwiceday6returningundergoassessmentsResults:Forty-three5averagescoreimprovementincreasing247±830±98BasednormativedataincreasenumbernormosmicparticipantsthresholdvaluesSpecificgeneralolfaction-relatedqualitylifeimproved4Conclusions:functionappearedimproveperipheralFuturecontrolledstudiesmustconfirmrolejustifynewtherapeuticstrategiesmayfocuscentralTrainingPost-COVID-19Disorders:ValueNormalizationThresholdIdentificationolfactionparosmia

Similar Articles

Cited By